Open AccessHow Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging
Author(s) -
Henri Zenuni,
Piergiorgio Grillo,
Giulia Maria Sancesario,
Sergio Bernardini,
Nicola Biagio Mercuri,
Tommaso Schirinzi
Publication year - 2021
Publication title -
journal of alzheimer's disease reports
Language(s) - English
Resource type - Journals
ISSN - 2542-4823
DOI - 10.3233/adr-200280
Subject(s) - cerebrospinal fluid , comorbidity , neurodegeneration , neurogranin , medicine , disease , dementia , neurology , neuropathology , oxidative stress , amyloid (mycology) , oncology , neuroscience , pathology , psychology , psychiatry , biology , phosphorylation , biochemistry , protein kinase c
Systemic comorbidity precipitates the risk for dementia. To comprehend the underlying mechanisms into a therapeutic perspective, we analyzed how comorbidity affects neurodegeneration-related cerebrospinal fluid (CSF) biomarkers of 55 cognitively intact subjects. The Charson Comorbidity Index (CCI) was correlated with CSF amyloid-β42 (Aβ42), amyloid-β40, total-tau, 181-phosphorylated-tau (p-tau), the Aβ42/p-tau ratio, neurogranin, and lactate. The age-related brain lesions at imaging were also considered. CCI had a raw association with Aβ42/p-tau and p-tau, and a stronger, age-independent correlation with lactate. These preliminary findings suggested that, in normal subjects, systemic comorbidity might increase CNS oxidative stress and, together with aging, contribute to develop an Alzheimer’s disease-like biochemical profile.